| Literature DB >> 25907424 |
Ryoko Mabuchi1, Takeshi Hara1, Takuro Matsumoto1, Yuhei Shibata1, Nobuhiko Nakamura1, Hiroshi Nakamura1, Junichi Kitagawa1, Nobuhiro Kanemura1, Naoe Goto1, Masahito Shimizu1, Hiroyasu Ito2, Yasuko Yamamoto3, Kuniaki Saito3, Hisataka Moriwaki1, Hisashi Tsurumi1.
Abstract
The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 μM. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 μM (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.Entities:
Keywords: L-kynurenine; L-tryptophan catabolism; acute myeloid leukemia (AML); immunological tolerance; indoleamine 2,3-dioxygenase; prognostic factor
Mesh：
Substances：
Year: 2015 PMID： 25907424 DOI： 10.3109/10428194.2015.1041388
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022